ArticleCureus2025
Neuroendocrine Sarcoidosis: A Rare Bird.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hypopituitarism Revealing Probable Neurosarcoidosis: A Case Report and Diagnostic Challenges.Reports (MDPI) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a systemic auto-inflammatory disease of unknown etiology. It is characterized by granuloma formation and can affect any organ. While it commonly affects the lungs and the lymphatic system, it can also involve the central nervous system, leading to neurosarcoidosis or the endocrine system and subsequent multiple endocrinal pathologies. Neurosarcoidosis can affect any part of the nervous system and therefore manifests with variable symptoms mimicking other neurological pathologies. Any endocrine gland can be infiltrated by sarcoidosis; however, the pituitary gland and the hypothalamus are the most frequently infiltrated, while thyroid sarcoidosis cases remain rare. Only a biopsy of a suspected lesion is considered to be a definitive diagnostic method, which makes diagnosing central nervous system sarcoidosis particularly challenging. This case report highlights the challenges of diagnosing neuroendocrine sarcoidosis as the first presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.